459 related articles for article (PubMed ID: 31227915)
1. Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure.
Scheen AJ
Curr Cardiol Rep; 2019 Jun; 21(8):70. PubMed ID: 31227915
[TBL] [Abstract][Full Text] [Related]
2. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
Sano M
J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
[TBL] [Abstract][Full Text] [Related]
3. Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system.
Azzam O; Matthews VB; Schlaich MP
Curr Opin Nephrol Hypertens; 2022 Mar; 31(2):135-141. PubMed ID: 35086983
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Nat Rev Endocrinol; 2020 Oct; 16(10):556-577. PubMed ID: 32855502
[TBL] [Abstract][Full Text] [Related]
5. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension.
Tikkanen I; Chilton R; Johansen OE
Curr Opin Nephrol Hypertens; 2016 Mar; 25(2):81-6. PubMed ID: 26808705
[TBL] [Abstract][Full Text] [Related]
6. Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition.
Herat LY; Matthews J; Azzam O; Schlaich MP; Matthews VB
Curr Hypertens Rep; 2022 Mar; 24(3):67-74. PubMed ID: 35235172
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 Inhibitors and Mechanisms of Hypertension.
Briasoulis A; Al Dhaybi O; Bakris GL
Curr Cardiol Rep; 2018 Jan; 20(1):1. PubMed ID: 29349558
[TBL] [Abstract][Full Text] [Related]
8. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
Chrysant SG
Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
[TBL] [Abstract][Full Text] [Related]
9. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
10. Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension.
Kimura T; Sanada J; Shimoda M; Hirukawa H; Fushimi Y; Nishioka M; Kinoshita T; Okauchi S; Obata A; Kohara K; Tatsumi F; Kamei S; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Investig; 2018 Jul; 9(4):875-881. PubMed ID: 29110406
[TBL] [Abstract][Full Text] [Related]
11. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
Thomas MC; Cherney DZI
Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
[TBL] [Abstract][Full Text] [Related]
12. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
13. Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System.
Ansary TM; Nakano D; Nishiyama A
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717173
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
15. The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection.
Delanaye P; Scheen AJ
Diabetes Metab; 2021 Nov; 47(6):101285. PubMed ID: 34597788
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibition and kidney protection.
Nespoux J; Vallon V
Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
[TBL] [Abstract][Full Text] [Related]
18. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.
Jordan J; Tank J; Heusser K; Heise T; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC
J Am Soc Hypertens; 2017 Sep; 11(9):604-612. PubMed ID: 28757109
[TBL] [Abstract][Full Text] [Related]
19. The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors.
Kugathasan L; Dubrofsky L; Advani A; Cherney DZI
Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):15-34. PubMed ID: 36524239
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2013 May; 125(3):21-32. PubMed ID: 23748504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
